California-based Senti Biosciences receives $8M grant from CIRM for Phase 1 clinical trial of SENTI-202 CAR-NK therapy.

Senti Biosciences, a California-based biotech, has been awarded an $8M grant by the California Institute for Regenerative Medicines (CIRM) for its Phase 1 clinical trial of SENTI-202, a first-in-class, Logic Gated off-the-shelf CAR-NK therapy targeting CD33 and/or FLT3 expressing hematologic malignancies, including AML. Initial efficacy data expected by year-end 2024, with durability data in 2025.